ID16926A - Komposisi-komposisi antijamur dengan ketersediaan biologis yang lebih baik - Google Patents

Komposisi-komposisi antijamur dengan ketersediaan biologis yang lebih baik

Info

Publication number
ID16926A
ID16926A IDP971648A ID971648A ID16926A ID 16926 A ID16926 A ID 16926A ID P971648 A IDP971648 A ID P971648A ID 971648 A ID971648 A ID 971648A ID 16926 A ID16926 A ID 16926A
Authority
ID
Indonesia
Prior art keywords
antijamur
compositions
biological availability
better biological
better
Prior art date
Application number
IDP971648A
Other languages
English (en)
Indonesian (id)
Inventor
Lieven Elvire Colette Baert
Geert Verreck
Dany Thone
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID16926(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ID16926A publication Critical patent/ID16926A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDP971648A 1996-05-20 1997-05-19 Komposisi-komposisi antijamur dengan ketersediaan biologis yang lebih baik ID16926A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201430 1996-05-20
EP97200698 1997-03-07

Publications (1)

Publication Number Publication Date
ID16926A true ID16926A (id) 1997-11-20

Family

ID=26142825

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP971648A ID16926A (id) 1996-05-20 1997-05-19 Komposisi-komposisi antijamur dengan ketersediaan biologis yang lebih baik

Country Status (34)

Country Link
US (4) US6509038B2 (zh)
EP (1) EP0904060B1 (zh)
JP (1) JP3391801B2 (zh)
KR (1) KR19990044257A (zh)
CN (1) CN1165291C (zh)
AR (1) AR007195A1 (zh)
AT (1) ATE255883T1 (zh)
AU (1) AU722101B2 (zh)
BG (1) BG64368B1 (zh)
BR (1) BR9706897B1 (zh)
CA (1) CA2240161C (zh)
CY (1) CY2434B1 (zh)
CZ (1) CZ293841B6 (zh)
DE (1) DE69726729T2 (zh)
DK (1) DK0904060T3 (zh)
EA (1) EA001219B1 (zh)
EE (1) EE03902B1 (zh)
ES (1) ES2212810T3 (zh)
HK (1) HK1018002A1 (zh)
HR (1) HRP970270B1 (zh)
HU (1) HU227745B1 (zh)
ID (1) ID16926A (zh)
IL (1) IL124935A (zh)
MX (1) MX9805418A (zh)
MY (1) MY123827A (zh)
NO (1) NO320495B1 (zh)
NZ (1) NZ330739A (zh)
PL (1) PL188566B1 (zh)
PT (1) PT904060E (zh)
SI (1) SI0904060T1 (zh)
SK (1) SK284145B6 (zh)
TR (1) TR199801225T2 (zh)
TW (1) TW460282B (zh)
WO (1) WO1997044014A1 (zh)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
DE69808670T2 (de) * 1997-12-31 2003-07-03 Choongwae Pharma Corp., Seoul/Soul Herstellungsverfahren und zusammensetzung einer oralen zubereitung von itraconazol
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
JP2003531099A (ja) 1999-03-24 2003-10-21 エフ エム シー コーポレーション 改良された水溶解度をもつ医薬製剤
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP1296677A2 (en) * 2000-06-22 2003-04-02 Novartis AG Solid valsartan pharmaceutical compositions
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
CN100369904C (zh) 2001-02-14 2008-02-20 泰博特克药品有限公司 2-(取代-氨基)-苯并噻唑磺酰胺hiv蛋白酶抑制剂
AR035819A1 (es) 2001-04-09 2004-07-14 Tibotec Pharm Ltd 2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos
PT1387842E (pt) 2001-05-11 2009-07-20 Tibotec Pharm Ltd 2-aminobenzoxazolsulfonamidas inibidoras de largo espectro da protease hiv
WO2002100407A1 (en) * 2001-06-12 2002-12-19 Smartrix Technologies Inc. Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
EP1463502B1 (en) 2001-12-21 2011-07-13 Tibotec Pharmaceuticals Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
RU2293721C2 (ru) * 2002-02-28 2007-02-20 Джапан Тобакко Инк. Сложноэфирные соединения и их применение в медицине
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
SI1517899T1 (sl) 2002-05-17 2008-02-29 Tibotec Pharm Ltd Substituirani benzoksazol sulfonamidi sirokega spektra, ki so HIV proteazni inhibitorji
JP2005538973A (ja) * 2002-07-04 2005-12-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 異なる２種類のポリマーマトリックスを含んで成る固体分散体
KR100994759B1 (ko) 2002-08-14 2010-11-16 티보텍 파마슈티컬즈 광역스펙트럼의 치환된 옥신돌 설폰아미드 ｈｉｖ프로테아제 저해제
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
DK1438961T4 (da) * 2003-01-14 2014-11-17 Acino Pharma Ag Bioækvivalent sammensætning af itraconazol dispergeret i en hydrofil polymer
CA2509958A1 (en) * 2003-02-03 2004-08-19 Novartis Ag Pharmaceutical formulation
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
CN1822843B (zh) * 2003-07-17 2010-04-28 泰博特克药品有限公司 制备含有抗病毒药物颗粒的方法
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005021486A1 (ja) 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
WO2005023242A1 (en) 2003-09-11 2005-03-17 Tibotec Pharmaceuticals Ltd. Entry inhibitors of the hiv virus
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
AU2005244121B2 (en) 2004-05-07 2012-01-19 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
CN1976930B (zh) 2004-05-17 2011-01-19 泰博特克药品有限公司 用作抗感染药物的6,7,8,9-取代的1-苯基-1,5-二氢吡啶并(3,2-b)吲哚-2-酮
EA012330B1 (ru) 2004-05-17 2009-08-28 Тиботек Фармасьютикалз Лтд. 1-ГЕТЕРОЦИКЛИЛ-1,5-ДИГИДРОПИРИДО[3,2-b]ИНДОЛ-2-ОНЫ
JP4879889B2 (ja) 2004-05-17 2012-02-22 テイボテク・フアーマシユーチカルズ・リミテツド ４−置換−１，５−ジヒドロ−ピリド［３，２−ｂ］インドール−２−オン
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR100708974B1 (ko) * 2004-07-19 2007-04-18 주식회사종근당 수용성 수지를 이용한 이트라코나졸 고체분산체
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
CA2598204C (en) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CA2618255C (en) 2005-08-08 2015-05-26 Abbott Gmbh & Co. Kg Itraconazole compositions with improved bioavailability
PT1912626T (pt) * 2005-08-08 2016-07-20 Abbvie Deutschland Formas farmacêuticas com biodisponibilidade melhorada
ES2403006T3 (es) * 2005-08-22 2013-05-13 The Johns Hopkins University Antagonistas de la vía Hedgehog para tratar enfermedades
CA2642761A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
WO2007113290A1 (en) 2006-04-03 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8486423B2 (en) * 2007-08-21 2013-07-16 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
ES2560899T3 (es) 2007-09-14 2016-02-23 Wockhardt Limited Composiciones de diacereína
EP2207532B1 (en) 2007-09-27 2012-08-29 Wockhardt Limited Pharmaceutical compositions of rhein or diacerein
US20090130160A1 (en) * 2007-11-21 2009-05-21 Fiber Innovation Technology, Inc. Fiber for wound dressing
EP2224923A4 (en) 2007-11-28 2013-05-15 Sequoia Pharmaceuticals Inc COMPOSITIONS AND METHOD FOR INHIBITING ZYTOCHROM P450 2D6
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009079521A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
JP2011509283A (ja) * 2008-01-11 2011-03-24 シプラ・リミテッド 固体医薬剤形
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (en) 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2285351A2 (en) * 2008-04-15 2011-02-23 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EA200900145A1 (ru) * 2008-12-31 2010-02-26 Открытое Акционерное Общество "Верофарм" Противогрибковое средство для вагинального применения
CN101780046B (zh) * 2009-01-16 2011-09-21 北京化工大学 一种伊曲康唑复合粉体及其制备方法
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2511145T3 (es) * 2010-10-14 2014-10-22 Abbott Gmbh & Co. Kg Formulación de dispersión sólida de curcuminoides
CN102068416A (zh) * 2010-12-30 2011-05-25 安徽先求药业有限公司 一种含有伊曲康唑的口服固体制剂及其制备方法
MX2013008476A (es) 2011-02-17 2013-08-12 Hoffmann La Roche Proceso para cristalizacion controlada de un ingrediente farmaceutico activo a partir del estado liquido superenfriado por extrusion de fusion en caliente.
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
AU2012295397A1 (en) * 2011-08-16 2014-02-20 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
WO2013024358A2 (en) 2011-08-18 2013-02-21 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
WO2013046045A1 (en) 2011-09-27 2013-04-04 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
WO2013192566A1 (en) 2012-06-21 2013-12-27 Mayne Pharma International Pty. Ltd. Itraconazole compositions and dosage forms, and methods of using the same
PT2874607T (pt) 2012-07-17 2017-08-14 Dow Global Technologies Llc Resumo
US20170071930A1 (en) 2012-11-19 2017-03-16 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
MX2015008911A (es) 2013-01-22 2015-10-22 Hoffmann La Roche Composicion farmaceutica con biodisponibilidad mejorada.
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
EP3094656B1 (en) 2014-01-16 2019-07-17 Dow Global Technologies LLC Support materials for 3d printing
WO2016200673A1 (en) * 2015-06-09 2016-12-15 Dow Global Technologies Llc Support materials for 3d printing
MA44987A (fr) * 2016-05-09 2019-03-20 Dispersol Technologies Llc Formulations de médicaments améliorées
EP3675832A1 (en) 2017-09-01 2020-07-08 Jordan Sweden Medical and Sterilization Company Fast self dispersible dosage forms of deferasirox
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用
CA3152307A1 (en) * 2019-08-28 2021-03-04 Lubrizol Advanced Materials, Inc. Drug-polymer amorphous solid dispersions using linear poly(acrylic acid) polymers
KR102266145B1 (ko) * 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
EP4392024A1 (en) 2021-08-25 2024-07-03 Basf Se Direct tableting auxiliary composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
EP0012523B2 (en) 1978-11-20 1988-02-03 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
WO1992018106A1 (en) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
EP0631578B1 (en) * 1992-03-18 2001-05-23 Janssen Pharmaceutica N.V. Itraconazole and saperconazole stereoisomers
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
JP3413238B2 (ja) * 1993-03-31 2003-06-03 オリンパス光学工業株式会社 位相制御膜構造体
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
JP2948111B2 (ja) 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物

Also Published As

Publication number Publication date
NO320495B1 (no) 2005-12-12
CZ188598A3 (cs) 1998-11-11
BR9706897B1 (pt) 2010-09-21
MX9805418A (es) 1998-10-31
CN1209740A (zh) 1999-03-03
HRP970270B1 (en) 2005-02-28
JPH11509238A (ja) 1999-08-17
NZ330739A (en) 1999-06-29
DE69726729T2 (de) 2004-12-02
CZ293841B6 (cs) 2004-08-18
ES2212810T3 (es) 2004-08-01
BG64368B1 (bg) 2004-12-30
CN1165291C (zh) 2004-09-08
IL124935A (en) 2001-06-14
TR199801225T2 (xx) 1998-11-23
HU227745B1 (en) 2012-02-28
AR007195A1 (es) 1999-10-13
KR19990044257A (ko) 1999-06-25
HUP9901620A2 (hu) 1999-10-28
AU722101B2 (en) 2000-07-20
AU2956297A (en) 1997-12-09
US6509038B2 (en) 2003-01-21
US20060263436A1 (en) 2006-11-23
US9642806B2 (en) 2017-05-09
SK284145B6 (sk) 2004-10-05
US20030082239A1 (en) 2003-05-01
PL330931A1 (en) 1999-06-07
NO982599D0 (no) 1998-06-05
BG102532A (en) 1999-02-26
PL188566B1 (pl) 2005-02-28
PT904060E (pt) 2004-04-30
EA199800571A1 (ru) 1998-12-24
WO1997044014A1 (en) 1997-11-27
CA2240161A1 (en) 1997-11-27
IL124935A0 (en) 1999-01-26
TW460282B (en) 2001-10-21
DE69726729D1 (de) 2004-01-22
HK1018002A1 (en) 1999-12-10
CY2434B1 (en) 2004-11-12
US8591948B2 (en) 2013-11-26
EP0904060B1 (en) 2003-12-10
NO982599L (no) 1998-11-19
MY123827A (en) 2006-06-30
US20010007678A1 (en) 2001-07-12
EP0904060A1 (en) 1999-03-31
HUP9901620A3 (en) 2000-03-28
BR9706897A (pt) 1999-08-31
EE9800304A (et) 1999-02-15
US20140134244A1 (en) 2014-05-15
US7081255B2 (en) 2006-07-25
ATE255883T1 (de) 2003-12-15
SI0904060T1 (en) 2004-04-30
CA2240161C (en) 2005-05-24
DK0904060T3 (da) 2004-04-13
SK84898A3 (en) 1999-03-12
EE03902B1 (et) 2002-12-16
EA001219B1 (ru) 2000-12-25
JP3391801B2 (ja) 2003-03-31
HRP970270A2 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
ID16926A (id) Komposisi-komposisi antijamur dengan ketersediaan biologis yang lebih baik
DE69718508D1 (de) Antitraspirant zusammensetzung
IS5430A (is) Ný samsetning
NO985460D0 (no) Limsammensetning
AT503376A3 (de) Synergistische spot-on-formulierung
FR2751202B1 (fr) Implant squelettique
DK1298194T3 (da) Staniolholdige sammensætninger
DE69731542D1 (de) Photokatalytische zusammensetzung
ID25508A (id) Komposisi dematologis
ID18359A (id) Komposisi mikrokapsul
DE69902473D1 (de) Kosmetikzusammensetzung
ATE293672T1 (de) Farbschonende zusammensetzungen
ID26317A (id) Formulasi pelepasan yang diperpanjang
DE69719442D1 (de) Frisierschaum-Zusammensetzungen
DE69718759D1 (de) Selbstschäumbare Fluorpolymerzusammensetzung
ID21770A (id) Plester yang mengandung felbinak
DE69704919D1 (de) Grundierzusammensetzung
ID23250A (id) Komposisi paroksetin
ID25650A (id) Komposisi-komposisi sampo
DE69717034D1 (de) Lippenstift Präparat
ID21906A (id) Komposisi adesif
ID16154A (id) Komposisi monomer yang distabilisasi
ITTV970086A0 (it) Struttura di pattino
ID19589A (id) Komposisi
ID16956A (id) Komposisi antijamur dengan ketersediaan hayati yang tertingkatkan